![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PSMA6 |
Gene summary for PSMA6 |
![]() |
Gene information | Species | Human | Gene symbol | PSMA6 | Gene ID | 5687 |
Gene name | proteasome 20S subunit alpha 6 | |
Gene Alias | IOTA | |
Cytomap | 14q13.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P60900 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5687 | PSMA6 | sample1 | Human | Cervix | CC | 2.89e-10 | 5.91e-01 | 0.0959 |
5687 | PSMA6 | sample3 | Human | Cervix | CC | 1.40e-82 | 1.03e+00 | 0.1387 |
5687 | PSMA6 | H2 | Human | Cervix | HSIL_HPV | 3.68e-13 | 4.52e-01 | 0.0632 |
5687 | PSMA6 | T1 | Human | Cervix | CC | 4.16e-17 | 5.04e-01 | 0.0918 |
5687 | PSMA6 | T3 | Human | Cervix | CC | 2.20e-75 | 1.04e+00 | 0.1389 |
5687 | PSMA6 | LZE2D | Human | Esophagus | HGIN | 2.90e-10 | 8.43e-01 | 0.0642 |
5687 | PSMA6 | LZE2T | Human | Esophagus | ESCC | 3.55e-16 | 1.73e+00 | 0.082 |
5687 | PSMA6 | LZE3D | Human | Esophagus | HGIN | 6.21e-05 | 1.07e+00 | 0.0668 |
5687 | PSMA6 | LZE4T | Human | Esophagus | ESCC | 4.00e-56 | 1.85e+00 | 0.0811 |
5687 | PSMA6 | LZE5T | Human | Esophagus | ESCC | 3.00e-33 | 2.09e+00 | 0.0514 |
5687 | PSMA6 | LZE7T | Human | Esophagus | ESCC | 3.06e-37 | 1.47e+00 | 0.0667 |
5687 | PSMA6 | LZE8T | Human | Esophagus | ESCC | 3.39e-38 | 1.29e+00 | 0.067 |
5687 | PSMA6 | LZE20T | Human | Esophagus | ESCC | 2.58e-39 | 1.31e+00 | 0.0662 |
5687 | PSMA6 | LZE21D1 | Human | Esophagus | HGIN | 3.53e-05 | 7.97e-01 | 0.0632 |
5687 | PSMA6 | LZE22D1 | Human | Esophagus | HGIN | 3.37e-23 | 7.49e-01 | 0.0595 |
5687 | PSMA6 | LZE22T | Human | Esophagus | ESCC | 2.40e-30 | 2.05e+00 | 0.068 |
5687 | PSMA6 | LZE24D1 | Human | Esophagus | HGIN | 3.66e-03 | 1.13e+00 | 0.054 |
5687 | PSMA6 | LZE24T | Human | Esophagus | ESCC | 7.89e-71 | 1.95e+00 | 0.0596 |
5687 | PSMA6 | LZE22D3 | Human | Esophagus | HGIN | 3.01e-07 | 1.14e+00 | 0.0653 |
5687 | PSMA6 | LZE21T | Human | Esophagus | ESCC | 4.10e-31 | 2.06e+00 | 0.0655 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
GO:00510915 | Cervix | CC | positive regulation of DNA-binding transcription factor activity | 51/2311 | 260/18723 | 5.05e-04 | 4.92e-03 | 51 |
GO:00510923 | Cervix | CC | positive regulation of NF-kappaB transcription factor activity | 32/2311 | 152/18723 | 1.62e-03 | 1.25e-02 | 32 |
GO:005072711 | Cervix | HSIL_HPV | regulation of inflammatory response | 41/737 | 386/18723 | 8.30e-09 | 1.03e-06 | 41 |
GO:005109211 | Cervix | HSIL_HPV | positive regulation of NF-kappaB transcription factor activity | 20/737 | 152/18723 | 2.25e-06 | 9.41e-05 | 20 |
GO:005109012 | Cervix | HSIL_HPV | regulation of DNA-binding transcription factor activity | 35/737 | 440/18723 | 6.77e-05 | 1.58e-03 | 35 |
GO:005109112 | Cervix | HSIL_HPV | positive regulation of DNA-binding transcription factor activity | 24/737 | 260/18723 | 1.01e-04 | 2.16e-03 | 24 |
GO:001049826 | Esophagus | HGIN | proteasomal protein catabolic process | 139/2587 | 490/18723 | 1.20e-17 | 3.41e-15 | 139 |
GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
GO:00510918 | Esophagus | ESCC | positive regulation of DNA-binding transcription factor activity | 155/8552 | 260/18723 | 3.83e-06 | 4.14e-05 | 155 |
GO:00510926 | Esophagus | ESCC | positive regulation of NF-kappaB transcription factor activity | 91/8552 | 152/18723 | 2.91e-04 | 1.75e-03 | 91 |
GO:001049812 | Liver | Cirrhotic | proteasomal protein catabolic process | 216/4634 | 490/18723 | 2.52e-21 | 9.29e-19 | 216 |
GO:001049822 | Liver | HCC | proteasomal protein catabolic process | 351/7958 | 490/18723 | 6.92e-40 | 1.46e-36 | 351 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:00510913 | Liver | HCC | positive regulation of DNA-binding transcription factor activity | 131/7958 | 260/18723 | 5.98e-03 | 2.45e-02 | 131 |
GO:00104988 | Lung | IAC | proteasomal protein catabolic process | 90/2061 | 490/18723 | 6.69e-07 | 3.89e-05 | 90 |
GO:00510903 | Lung | IAC | regulation of DNA-binding transcription factor activity | 76/2061 | 440/18723 | 4.44e-05 | 1.05e-03 | 76 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0305014 | Cervix | CC | Proteasome | 16/1267 | 46/8465 | 6.69e-04 | 3.09e-03 | 1.83e-03 | 16 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0501019 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0305015 | Cervix | CC | Proteasome | 16/1267 | 46/8465 | 6.69e-04 | 3.09e-03 | 1.83e-03 | 16 |
hsa0501225 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
hsa0502024 | Cervix | HSIL_HPV | Prion disease | 40/459 | 273/8465 | 6.26e-09 | 3.67e-07 | 2.97e-07 | 40 |
hsa0501624 | Cervix | HSIL_HPV | Huntington disease | 38/459 | 306/8465 | 1.21e-06 | 2.54e-05 | 2.05e-05 | 38 |
hsa0502224 | Cervix | HSIL_HPV | Pathways of neurodegeneration - multiple diseases | 46/459 | 476/8465 | 8.10e-05 | 1.08e-03 | 8.72e-04 | 46 |
hsa0501024 | Cervix | HSIL_HPV | Alzheimer disease | 38/459 | 384/8465 | 2.13e-04 | 2.31e-03 | 1.86e-03 | 38 |
hsa0501424 | Cervix | HSIL_HPV | Amyotrophic lateral sclerosis | 35/459 | 364/8465 | 6.43e-04 | 5.23e-03 | 4.23e-03 | 35 |
hsa0501235 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
hsa0502034 | Cervix | HSIL_HPV | Prion disease | 40/459 | 273/8465 | 6.26e-09 | 3.67e-07 | 2.97e-07 | 40 |
hsa0501634 | Cervix | HSIL_HPV | Huntington disease | 38/459 | 306/8465 | 1.21e-06 | 2.54e-05 | 2.05e-05 | 38 |
hsa0502234 | Cervix | HSIL_HPV | Pathways of neurodegeneration - multiple diseases | 46/459 | 476/8465 | 8.10e-05 | 1.08e-03 | 8.72e-04 | 46 |
hsa0501034 | Cervix | HSIL_HPV | Alzheimer disease | 38/459 | 384/8465 | 2.13e-04 | 2.31e-03 | 1.86e-03 | 38 |
hsa0501434 | Cervix | HSIL_HPV | Amyotrophic lateral sclerosis | 35/459 | 364/8465 | 6.43e-04 | 5.23e-03 | 4.23e-03 | 35 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
PSMA6 | iATC | Thyroid | ATC | CXCL6,IDO1,CCL20, etc. | 1.76e-01 | ![]() |
PSMA6 | TFC | Thyroid | goiters | CXCL6,IDO1,CCL20, etc. | 1.54e-01 | ![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PSMA6 | deletion | Frame_Shift_Del | c.546delA | p.Val183Ter | p.V183* | P60900 | protein_coding | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
PSMA6 | SNV | Missense_Mutation | novel | c.322N>C | p.Glu108Gln | p.E108Q | P60900 | protein_coding | deleterious(0.04) | benign(0.038) | TCGA-55-7907-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PSMA6 | SNV | Missense_Mutation | c.106G>A | p.Gly36Ser | p.G36S | P60900 | protein_coding | deleterious(0.04) | possibly_damaging(0.518) | TCGA-91-6829-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PSMA6 | insertion | Frame_Shift_Ins | novel | c.588_588+1insACTGCAATTACATGCCT | p.Ser203LeufsTer19 | p.S203Lfs*19 | P60900 | protein_coding | TCGA-39-5016-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
PSMA6 | SNV | Missense_Mutation | novel | c.8G>A | p.Arg3His | p.R3H | P60900 | protein_coding | deleterious(0.03) | benign(0.226) | TCGA-BA-A6DL-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR |
PSMA6 | insertion | Frame_Shift_Ins | novel | c.588_588+1insACTGCAATTACATGCCT | p.Ser203LeufsTer19 | p.S203Lfs*19 | P60900 | protein_coding | TCGA-CV-A45W-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
PSMA6 | SNV | Missense_Mutation | novel | c.522N>C | p.Glu174Asp | p.E174D | P60900 | protein_coding | deleterious(0.04) | benign(0.105) | TCGA-XQ-A8TA-01 | Prostate | prostate adenocarcinoma | Male | <65 | 10 | Unknown | Unknown | PD |
PSMA6 | SNV | Missense_Mutation | c.449A>G | p.Gln150Arg | p.Q150R | P60900 | protein_coding | tolerated(0.15) | benign(0.119) | TCGA-BR-8078-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PSMA6 | SNV | Missense_Mutation | c.562N>C | p.Asp188His | p.D188H | P60900 | protein_coding | deleterious(0.02) | benign(0.05) | TCGA-CD-8529-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | epirubicin | CR | |
PSMA6 | SNV | Missense_Mutation | c.218N>A | p.Thr73Asn | p.T73N | P60900 | protein_coding | deleterious(0.03) | benign(0.271) | TCGA-EQ-A4SO-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL451887 | CARFILZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CARFILZOMIB | CARFILZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL2103884 | OPROZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL325041 | BORTEZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL371405 | MARIZOMIB | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | CARFILZOMIB | CARFILZOMIB | 24524217 | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | CHEMBL3545432 | IXAZOMIB CITRATE | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | BORTEZOMIB | BORTEZOMIB | 24524217 | |
5687 | PSMA6 | PROTEASE, DRUGGABLE GENOME | inhibitor | BORTEZOMIB | BORTEZOMIB |
Page: 1 |